|
Canada-0-Proofreading Azienda Directories
|
Azienda News:
- NGM Bio
LATEST NGM BIO NEWS Meet Our Team We have an experienced and talented team of drug developers using their capabilities and expertise to advance innovative therapeutics for serious unmet needs
- NGM Biopharma技术全梳理 点击上方的 行舟Drug 添加关注 . . .
点击上方的 行舟Drug 添加关注 Armstrong NGM Biopharmaceuticals成立于2008年，早期专注于肝病 代谢病药物研发，后来逐渐拓展至眼病
- 临床阶段生物制药公司：NGM Biopharmaceuticals (NGM)
NGM Biopharmaceuticals, Inc (NASDAQ:NGM)创立于2007年12月，总部位于美国加州South San Francisco，全职雇员225人，是一家临床阶段的 生物制药公司，基于公司对心脏代谢，肝脏，肿瘤和眼科疾病的关键生物学途径的科学理解，开发新型疗法。
- NGM Biopharmaceuticals, Inc. (NGM Biopharmaceuticals, Inc . . .
子公司 | 2007 | California, United States | 100-250 | NASDAQ: NGM | www ngmbio com 更新于：2026-02-15 概览 管线布局
- NGM Bio完成1. 22亿美元A轮融资 - Pharmcube
7月17日，加利福尼亚州南旧金山，专注于发现和开发患者变革疗法的私人生物技术公司NGM Bio宣布完成1 22亿美元的A轮融资，融资由TCG领投，并有一批精选投资者跟投。
- 变革性治疗药物开发商NGM Bio宣布完成1. 22亿美元A轮融资 . . .
(NGM Bio), a privately held biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced a $122 million Series A financing led by TCG with participation from a select group of investors
- NGM Biopharmaceuticals_NGM BIOPHARMACEUTICALS . . .
基本信息 修改信息 企业简称 NGM Biopharmaceuticals 企业全称 NGM BIOPHARMACEUTICALS INC 成立时间 - 融资阶段 战略投资 市值 估值 - 人员规模 - 一级行业 医疗健康 企业网址 https: www ngmbio com 运营状态 运营中 公司类型 实体企业 一句话简介 美国临床阶段生物制药
- About NGM – NGM Bio
In addition to advancing our lead candidate NGM120 in hyperemesis gravidarum and cancer cachexia, we have partnering opportunities available for several liver and oncology programs Visit our Pipeline page to learn more about these candidates Email bd@ngmbio com to learn more about partnering with NGM
- Ngm Bio Holdings, Inc. (Ngm Bio Holdings, Inc. ) - 药物管线 . . .
About NGM BioNGM Biopharmaceuticals, Inc (NGM Bio), a wholly owned subsidiary of NGM Bio Holdings, Inc , a clinical-stage, privately held biotechnology company, is focused on discovering and developing novel, life-changing medicines for people whose health and lives have been disrupted by disease
- NGM Bio公布了正在进行的NGM707治疗晚期实体瘤试验的 . . .
NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet Need
|
|